Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
Nyxol
APX3330
APX2009
Posters and Publications
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Enrolling
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Last Patient Last Visit Completed
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed
MIRA-3
Completed
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Completed
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Completed
Partnerships
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
For more details,
click here for the full news release.
Continue
Presentations
News & Media
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Corporate Presentation
Ocuphire ZETA-1 Topline Results Conference Call Presentation
OIS XII, Retina Innovation Showcase
Ocuphire APX3330 KOL Event October 2022
OIS Retina 2022 - Mina Sooch
MIRA-3 Topline Results Conference Call Presentation
2022 Investor R&D Day Presentation
[email protected]
Presentation
VEGA-1 TopLine Data Results Conference Call Presentation
MIRA-2 Phase 3 Trial Results Conference Call Presentation